Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

AJMC
Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
February 17th 2018

eAppendix

Dave Nellesen, PhD Katerine Dea, MSc Annie Guerin, MSc Kenneth W. Culver, MD Alex Mutebi, PhD Anand Dalal, MBA, BSPharm
Site Logo
February 16th 2018

Development of a Tailored Survey to Evaluate a Patient-Centered Initiative

Marcy Winget, PhD Farnoosh Haji-Sheikhi, MS Steve M. Asch, MD, MPH
We developed short patient experience surveys that were sensitive to our broad quality initiative, were meaningful and acceptable to patients, and had good response rates.
AJMC® in the Press, February 16, 2018
February 16th 2018

AJMC® in the Press, February 16, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Roche Acquires Flatiron Health for $1.9 Billion
February 16th 2018

Roche Acquires Flatiron Health for $1.9 Billion

Mary Caffrey
Flatiron Health expects to maintain its current business model in the transaction.
Nat Turner on the Main Barriers for Flatiron Health in Providing Care in Oncology
February 16th 2018

Nat Turner on the Main Barriers for Flatiron Health in Providing Care in Oncology

Nat Turner, co-founder and CEO of Flatiron Health, says that clinical research accessibility is one of the biggest barriers in oncology care that Flatiron Health is working to remove.
Site Logo
February 15th 2018

Pricing of Monoclonal Antibody Therapies: Higher If Used for Cancer?

Inmaculada Hernandez, PharmD, PhD Samuel W. Bott, BS Anish S. Patel, BS Collin G. Wolf, BS Alexa R. Hospodar, BS Shivani Sampathkumar, BS William H. Shrank, MD, MSHS
The annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.
Family History Associated With Breast Cancer Risk for Women 65 and Older
February 15th 2018

Family History Associated With Breast Cancer Risk for Women 65 and Older

Jaime Rosenberg
First-degree family history was associated with an increased risk of breast cancer among women aged 65 and older, and risk associated with family history was not significantly modified by breast density, according to a study in JAMA Oncology.
FDA Approves Apalutamide, First Treatment for Nonmetastatic Castration-Resistant Prostate Cancer
February 15th 2018

FDA Approves Apalutamide, First Treatment for Nonmetastatic Castration-Resistant Prostate Cancer

Laura Joszt, MA
FDA has approved apalutamide, the first treatment for nonmetastatic castration-resistant prostate cancer, based on results from a phase 3 study that showed the drug reduced the risk of metastasis or death by 72% and improved median metastasis-free survival by more than 2 years.
Site Logo
February 15th 2018

ASCO and NCCN Release Guidelines on Managing Immunotherapy-Related Toxicities

Kelly Davio
The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) have developed new guidelines on managing immune checkpoint inhibitor-related toxicities.
Site Logo
February 14th 2018

Pembrolizumab Associated With Increased Overall Survival in Patients With Urothelial Cancer

Jaime Rosenberg
There is a greater overall survival benefit for patients with recurrent urothelial cancer being treated with pembrolizumab versus chemotherapy, according to long-term results of the KEYNOTE-045 trial.
ASCO Review Finds Clinical Pathway Programs Adhere to Guidelines
February 13th 2018

ASCO Review Finds Clinical Pathway Programs Adhere to Guidelines

Samantha DiGrande
Last week, the American Society of Clinical Oncology (ASCO) published its review of the leading oncology pathway vendors in the United States in the Journal of Oncology Practice. The report found that overall, the prominent commercial pathway programs in the United States are aligned with ASCO’s evaluation criteria.
Kentucky's Medicaid Expansion Associated With Improved Breast Cancer Care
February 13th 2018

Kentucky's Medicaid Expansion Associated With Improved Breast Cancer Care

Jaime Rosenberg
Medicaid expansion in Kentucky led to an increase of screening mammograms, screening coverage, and breast-conserving surgery for women aged 20 to 64 with breast cancer, according to a study published in the Journal of the American College of Surgeons. However, the study also showed that time from diagnosis to operation increased post expansion and time from operation to chemotherapy remained unchanged.
Dr Roger Brito Discusses Practitioners Taking on 2-Sided Risk
February 12th 2018

Dr Roger Brito Discusses Practitioners Taking on 2-Sided Risk

We want to know all sides of the 2-risk model, like with any challenge or strategy, said Roger Brito, DO, national director for oncology, Aetna.
Dr Sumit Subudhi Discusses Immune Checkpoint Inhibitors in Prostate Cancer
February 11th 2018

Dr Sumit Subudhi Discusses Immune Checkpoint Inhibitors in Prostate Cancer

In prostate cancer, we're using combinations by looking to see how 1 drug may trigger an immune infiltrate or proteins that allow the tumor to resist the monotherapy, said Sumit Subudhi, MD, PhD, genitourinary medical oncology, MD Anderson Cancer Center.
Podcast: This Week in Managed Care—Cancer Survival Rates and Other Health News
February 10th 2018

Podcast: This Week in Managed Care—Cancer Survival Rates and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Site Logo
February 10th 2018

Docetaxel Plus Hormone Therapy Improved QoL, Cost Effectiveness in Prostate Cancer

Jaime Rosenberg
The addition of docetaxel to first-line long-term hormone therapy in patients with prostate cancer is associated with improved quality of life (QoL) benefits and cost effectiveness, according to study results presented at the 2018 Genitourinary Cancers Symposium.
Site Logo
February 10th 2018

Medicaid Expansion Led to Earlier Stage at Diagnosis of Testicular Cancer

Jaime Rosenberg
There was a reduced rate of uninsured patients at the time of diagnosis and a shift to earlier stage at time of diagnosis for patients with testicular cancer in states that adopted Medicaid expansion in 2014, according to findings presented at the 2018 Genitourinary Cancers Symposium.
Site Logo
February 10th 2018

Daily IGRT in Prostate Cancer Reduces Risk of Recurrence, Increases Risk of Second Cancer

Jaime Rosenberg
Daily image-guided radiotherapy, when compared to weekly control, decreases the risk of recurrence and rectal toxicity, but is associated with an increased risk of second cancer, according to study results presented at the 2018 Genitourinary Cancers Symposium.
Dr Christopher Kane on Robotic Procedures in Prostate Cancer
February 10th 2018

Dr Christopher Kane on Robotic Procedures in Prostate Cancer

Robotic procedures have really exploded in prostate cancer, said Christopher Kane, MD, professor of urology, University of California, San Diego. Robotic radical prostatectomy is now the most common way a radical prostatectomy is done in the United States.
Eligibility Requirements Exclude Black Patients From Prostate Cancer Clinical Trials
February 10th 2018

Eligibility Requirements Exclude Black Patients From Prostate Cancer Clinical Trials

Kaitlynn Ely
Black patients with prostate cancer are underrepresented in clinical trials due to eligibility requirements that exclude patients with benign ethnic neutropenia, according to a new study published in JAMA Oncology.
Site Logo
February 10th 2018

Use of Biomarkers to Identify Patients, Therapies for Neoadjuvant Chemotherapy

Jaime Rosenberg
During a session at the 2018 Genitourinary Cancers Symposium, Peter Black, MD, professor, department of urologic sciences, University of British Columbia, discussed using molecular subtypes, the Coxen model, and gene mutations to select patients and therapies for neoadjuvant chemotherapy.
Site Logo
February 10th 2018

Combining Radiation and Immunotherapy in Patients With Bladder Cancer

Jaime Rosenberg
During a session at the 2018 Genitourinay Cancers Symposium, Abhishek Solanki, MD, MS, assistant professor, radiation oncology, Loyola University of Chicago discussed the role of immunotherapy in patients undergoing radiation therapy for bladder cancer.
Site Logo
February 10th 2018

Guidelines for Management of Muscle-Invasive Bladder Cancer

Jaime Rosenberg
With new guidelines on how to treat and manage muscle-invasive bladder cancer, Jeffrey Holzbeierlein, MD, FACS, professor of urology, director of urologic oncology, interim chair of the department of urology, University of Kansas Health System, provided insight into how the guidelines have changed the management of the disease at the 2018 Genitourinary Cancers Symposium.
This Week in Managed Care: February 9, 2018
February 9th 2018

This Week in Managed Care: February 9, 2018

This week, the top managed care stories included Indiana being approved as the second state to implement work requirements in Medicaid; research found 5-year survival rates for cancer are increasing; coverage from the American Society of Clinical Oncology's 2018 Genitourinary Symposium.
Site Logo
February 9th 2018

Is There Evidence for Local Treatment for Newly Diagnosed Metastatic Prostate Cancer?

Jaime Rosenberg
During a session at the 2018 Genitourinary Cancers Symposium, 2 doctors debate whether there is existing evidence for local treatment for patients newly diagnosed with metastatic disease.
Dr Joe O'Sullivan on Molecular Therapies in Prostate Cancer
February 9th 2018

Dr Joe O'Sullivan on Molecular Therapies in Prostate Cancer

For the first time, molecular therapies, such as radium-223, provide a survival-prolonging agent for men with advanced prostate cancer affecting the bone, explained Joe O'Sullivan, MD, FRCR, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast.
Site Logo
February 9th 2018

Osteomimicry May Contribute to Uptake of Radium-223 Within Bone Metastases for Patients With mCRPC

Jaime Rosenberg
Osteomimicry may contribute to the uptake of radium-223 within bone metastases and may subsequently enhance the therapeutic benefit of radium-223, according to an abstract presented by Andrew Armstrong, MD, associate professor of medicine, Duke University School of Medicine, at the 2018 Genitourinary Cancers Symposium.
Site Logo
February 9th 2018

Apalutamide Significantly Improved Metastasis-Free Survival in Men With nmCRPC

Jaime Rosenberg
Apalutamide significantly improved median metastasis-free survival by 2 years in men with nonmetastatic castrate-resistant prostate cancer (nmCRPC), according to study results presented by Eric Jay Small, MD, MD, FASCO, chief of the division of hematology and oncology in the department of medicine at the University of California, San Francisco (UCSF), deputy director of the UCSF Helen Diller Family Comprehensive Cancer Center, and professor in residence in the Department of Medicine and Department of Urology, at the 2018 Genitourinary Cancers Symposium.
Long-Term Follow-Up of CAR T in ALL Indicates Early Treatment Extends Survival
February 9th 2018

Long-Term Follow-Up of CAR T in ALL Indicates Early Treatment Extends Survival

Laura Joszt, MA
A long-term follow-up analyzing the toxic effects and results from a phase 1 clinical trial of adult patients with relapsed B-cell acute lymphoblastic leukemia (ALL) who were treated with CD19-specific chimeric antigen receptor (CAR) T cells found patients with low disease burden had a longer medial overall survival and a lower incidence of toxicity.
Atezolizumab Treatment Safe and Effective in Metastatic Urothelial Cancer Patients
February 8th 2018

Atezolizumab Treatment Safe and Effective in Metastatic Urothelial Cancer Patients

Kaitlynn Ely
Patients with metastatic urothelial cancer treated with atezolizumab monotherapy demonstrated tolerability for the drug and general ability to manage adverse effects, according to a study published in JAMA Oncology.
<1
...
565758596061626364
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo